Sarepta Therapeutics (SRPT) Share-based Compensation (2010 - 2025)

Sarepta Therapeutics' Share-based Compensation history runs 16 years deep, the most recent figure standing at -$109.1 million for Q4 2025.

• On a quarterly basis, Share-based Compensation fell 319.48% year-over-year to -$109.1 million in Q4 2025; TTM through Mar 2026 was -$51.1 million, a 148.62% decrease from a year earlier, with the FY2025 full-year figure at $218.0 million, down 8.6% from the prior year.
• Share-based Compensation retreated to -$109.1 million in Q4 2025 per SRPT's latest filing, from $16.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $102.9 million in Q2 2022 and bottomed at -$109.1 million in Q4 2025.
• The 5-year median for Share-based Compensation is $41.4 million (2023), against an average of $26.4 million.
• Biggest YoY gain for Share-based Compensation was 395.64% in 2025; the steepest drop was 319.48% in 2025.
• Year by year, Share-based Compensation stood at -$70.9 million in 2021, then soared by 171.21% to $50.5 million in 2022, then decreased by 9.3% to $45.8 million in 2023, then advanced by 8.48% to $49.7 million in 2024, then slumped by 319.48% to -$109.1 million in 2025.
• Per Business Quant, the three latest SRPT Share-based Compensation figures stand at -$109.1 million (Q4 2025), $16.4 million (Q3 2025), and $41.6 million (Q2 2025).